SCHEMBL917082

SCHEMBL917082

CCOC(=O)c1cc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.68
CYP1A2 P05177 1/20 0.66
SMN1; SMN2 Q16637 3/20 0.57
ALDH1A1 P00352 7/20 0.53
LMNA P02545 5/20 0.53
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
KDM4E B2RXH2 6/20 0.51
HPGD P15428 3/20 0.50
RAB9A P51151 3/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPT P10636 4/20 0.49
NPC1 O15118 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
ATM Q13315 1/20 0.49
ALOX15 P16050 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295495 0.83 GPR84 (0.89) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL7551807 0.83 CYP2C19 (0.56) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL11129245 0.81 CYP1A2 (0.60) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL10681299 0.81 GPR84 (1.00) GPR84CYP1A2ALDH1A1LMNAKMT2A
SCHEMBL7183176 0.81 GPR84 (1.00) GPR84CYP1A2ALDH1A1LMNAKMT2A
SCHEMBL11129320 0.81 GPR84 (1.00) GPR84CYP1A2ALDH1A1LMNAKMT2A
SCHEMBL4283121 0.81 CYP1A2 (0.64) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL118496 0.79 CYP1A2 (1.00) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL692383 0.79 KMT2A (0.49) GPR84SMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL8709531 0.79 GPR84 (0.63) GPR84CYP1A2SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152239-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2017-06-01 US disclosed
US-20170152239-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2017-06-01 US disclosed
US-20170152239-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2017-06-01 US disclosed
US-20150239842-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2015-08-27 US disclosed
US-20150239842-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2015-08-27 US disclosed
US-20150239842-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS PFIZER INC. (US) 2015-08-27 US disclosed
EP-2900653-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS Pfizer Inc. (US) 2015-08-05 EP disclosed
US-8518939-B2 6-pyrimidinyl-pyrimid-4-one derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-27 US disclosed
US-8518939-B2 6-pyrimidinyl-pyrimid-4-one derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-27 US disclosed
US-8518939-B2 6-pyrimidinyl-pyrimid-4-one derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-27 US disclosed
EP-2078717-A1 6-Pyrimidinyl-pyrimid-2-one derivative sanofi-aventis (FR) 2009-07-15 EP disclosed
EP-2078717-A1 6-Pyrimidinyl-pyrimid-2-one derivative sanofi-aventis (FR) 2009-07-15 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed
WO-2009035162-A1 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-19 WO disclosed
WO-2009035162-A1 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-19 WO disclosed
WO-2009035159-A1 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-19 WO disclosed
WO-2009035159-A1 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-19 WO disclosed
EP-1910320-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2008-04-16 EP disclosed
WO-2007011065-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-25 WO disclosed
US-4094976-A ANTICOCCIDIAL CYCLICAMINO ETHANOLS AND ESTERS THEREOF MERCK & CO., INC. (US) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 GPR84 4320/4885CYP1A2 761/4885SMN1; SMN2 849/4885
US-20150239842-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS HRH2, H1-0, H1-2 GPR84 684/4885CYP1A2 226/4885SMN1; SMN2 3440/4885
US-20170152239-A1 BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS HRH2, HRH4, H1-0 GPR84 902/4885CYP1A2 237/4885SMN1; SMN2 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.